Although interpretation is limited by small sample size, these findings may suggest that the survival benefit associated with LAT may be mediated by enhanced early immune-mediated tumor killing in oligometastatic NSCLC and that ctDNA could be used post-LAT for the assessment of tumor response and/or early recurrence. Here, LAT is linked to non-small cell lung carcinoma.